Press release
Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape: DelveInsight Releases 2025 Competitive Intelligence Report Featuring 200+ Companies and 220+ Therapeutics Worldwide
Antibody-Drug Conjugates (ADCs) in Oncology Clinical Trials
DelveInsight, a prominent market research and strategic consulting company specializing in the life sciences industry, has unveiled its latest intelligence offering, "Antibody-Drug Conjugates (ADCs) - Competitive Landscape, 2025." This extensive report provides a panoramic view of the global ADC space, including detailed evaluations of more than 200 biopharmaceutical companies and 220+ ADC drug candidates, establishing it as one of the most authoritative resources available for stakeholders across the oncology continuum.
The report delivers exhaustive coverage of marketed products, developmental pipelines, clinical trial landscapes, corporate profiles, partnership activities, licensing trends, and regulatory progressions. It also sheds light on evolving scientific directions and critical unmet needs across the precision oncology domain.
Download the Complete Antibody-Drug Conjugates Competitive Landscape Report and Stay at the Forefront of Oncology Innovation @ https://www.delveinsight.com/report-store/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Antibody-Drug Conjugates: Transforming Precision Cancer Treatment
Antibody-Drug Conjugates have rapidly emerged as a transformative modality in oncology. By pairing highly specific monoclonal antibodies with potent cytotoxic agents, ADCs offer targeted tumor cell destruction while minimizing systemic toxicity-an advancement far superior to traditional chemotherapy approaches.
A typical Antibody-Drug Conjugates structure integrates:
• A monoclonal antibody targeting tumor-specific antigens
• A cytotoxic payload designed to induce apoptosis
• A specialized linker that supports plasma stability and precise intracellular release
This intricate design allows for selective tumor eradication through antigen binding, internalization, and controlled payload activation.
Since the approval of the first Antibody-Drug Conjugates, gemtuzumab ozogamicin (Mylotarg) in 2000, the field has seen continuous advancements in antibody engineering, linker chemistry, and payload optimization - positioning Antibody-Drug Conjugates as a leading therapeutic class in next-generation oncology.
Key Players Shaping the Global Antibody-Drug Conjugates Competitive Landscape
The report highlights innovators driving progress in the ADC sector, including:
• Jiangsu Hengrui Medicine
• Bio-Thera Solutions
• MediLink Therapeutics
• Byondis
• AbbVie
• Oxford BioTherapeutics
• Iksuda Therapeutics
• Novelty Nobility
• LegoChem Biosciences
• DualityBio
• Lepu Biopharma
• Ambrx
• CSPC ZhongQi Pharmaceutical Technology
• MacroGenics
• ADC Therapeutics
• Genor Biopharma
• CStone Pharmaceuticals
• AstraZeneca
• Alteogen
• Biocity Biopharmaceutics
• And many more global and emerging players.
Access Insights on 200+ Companies and 220+ ADCs - Download the Sample Report Today @ https://www.delveinsight.com/report-store/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Recent Breakthroughs in the Antibody-Drug Conjugates Development Pipeline
The Antibody-Drug Conjugates landscape has expanded at unprecedented speed, fueled by increasing investments, strategic alliances, and robust clinical activity. The report outlines several key developments, including:
• June 2024: Hudson Therapeutics collaborates with Shaperon to advance nanobody-based ADCs and radiopharmaceuticals.
• June 2024: The FDA issues a partial clinical hold on MediLink's YL202 Phase I trial due to dose-related concerns.
• October 2023: Daiichi Sankyo and Merck establish a major global partnership for three ADC assets-patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan.
• May 2023: Bliss Biopharmaceutical enters collaboration with Eisai for the continued clinical evaluation of BB-1701 (HER2-directed).
• April 2023: Byondis B.V. announces promising preclinical results for BYON3521.
• February 2023: Gilead's Trodelvy secures FDA approval for HR+/HER2- metastatic breast cancer based on strong Phase III data.
Explore the Complete Antibody-Drug Conjugates Pipeline and Market Outlook - Download Now @ https://www.delveinsight.com/sample-request/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Marketed Antibody-Drug Conjugates Therapies Leading Today's Oncology Care
Trodelvy (sacituzumab govitecan-hziy) - Gilead Sciences
• Targets Trop-2, found in most breast and bladder cancers
• Utilizes an SN-38 payload via a proprietary linker
• Approved for TNBC, HR+/HER2- mBC, and urothelial carcinoma
• Authorized in more than 40 countries
Padcev (enfortumab vedotin-ejfv) - Astellas Pharma
• Targets Nectin-4 in urothelial tumors
• Approved in combination with pembrolizumab for advanced urothelial cancer
Prominent Antibody-Drug Conjugates Pipeline Candidates to Watch
The report spotlights several high-potential Antibody-Drug Conjugates moving through late-stage and mid-stage development:
• SHR-A1811 (Jiangsu Hengrui Medicine) - HER2-targeting ADC, Phase III for breast cancer; also being evaluated in lung, gastric, and gynecologic cancers.
• Telisotuzumab vedotin (AbbVie) - c-MET-targeted ADC in Phase III for NSCLC.
• BAT8006 (Bio-Thera Solutions) - FRα-targeted ADC under Phase II assessment for ovarian cancer and other solid tumors.
• YL202 (MediLink Therapeutics) - HER3-directed Antibody-Drug Conjugates using tumor microenvironment activable linker technology, in Phase II.
• BYON3521 (Byondis) - c-MET Antibody-Drug Conjugates utilizing next-generation linker-payload design, currently in Phase I.
• IKS03 (Iksuda Therapeutics) - CD19-directed Antibody-Drug Conjugates for B-cell malignancies with a potent PBD payload.
Stay Updated on Emerging ADCs Driving the Future of Oncology - Get the Report @ @ https://www.delveinsight.com/sample-request/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
DelveInsight's Analytical Expertise on Antibody-Drug Conjugates Development
The Antibody-Drug Conjugates Competitive Landscape 2025 report encompasses:
• Profiles of 200+ companies active in ADC R&D
• Detailed therapeutic and pipeline analysis-platforms, dosing routes, developmental stages
• Evaluation of discontinued or suspended ADC programs
• Comprehensive review of collaborations, licensing deals, acquisitions, and partnerships
• Insights on evolving technologies including nanobody-ADCs, improved linker platforms, and microenvironment-activated ADCs
Key Strategic Questions the Report Addresses
• Which companies are leading the global Antibody-Drug Conjugates development race?
• What Antibody-Drug Conjugates have reached late-stage clinical development?
• Which organizations dominate the partnership, M&A, and licensing space?
• What technological innovations are defining next-generation Antibody-Drug Conjugates?
• Who are the emerging disruptors in the Antibody-Drug Conjugates market?
• What clinical trials are underway across tumor types, and what are their progression timelines?
Stay Ahead of Competitors - Access the Global Antibody-Drug Conjugates Landscape Report Today @ @ https://www.delveinsight.com/sample-request/antibody-drug-conjugates-adcs-in-oncology-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Unmet Needs and Future Growth Prospects in the Antibody-Drug Conjugates Market
Despite remarkable progress, Antibody-Drug Conjugates development faces challenges, including:
• Tumor resistance pathways
• Off-target toxicities
• Manufacturing complexity and scalability issues
However, advancements in bispecific Antibody-Drug Conjugates, novel payloads, and combination therapies are expected to address current limitations. With 220+ ADCs currently in development, the next decade is forecast to bring accelerated approvals and major commercial growth.
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody-Drug Conjugates (ADCs) in Oncology Competitive Landscape: DelveInsight Releases 2025 Competitive Intelligence Report Featuring 200+ Companies and 220+ Therapeutics Worldwide here
News-ID: 4292458 • Views: …
More Releases from DelveInsight Business Research
Atopic Dermatitis Pipeline 2025: FDA Approvals and Clinical Trials Landscape wit …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atopic Dermatitis pipeline constitutes 100+ key companies continuously working towards developing 120+ Atopic Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Atopic Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Ankylosing Spondylitis Pipeline 2025: Therapies, MOA Insights, and Key Clinical …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Ankylosing Spondylitis pipeline constitutes 20+ key companies continuously working towards developing 20+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Ankylosing Spondylitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also…
Diabetic Foot Ulcers Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Foot Ulcers pipeline constitutes 20+ key companies continuously working towards developing 25+ Diabetic Foot Ulcers treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Diabetic Foot Ulcers Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The…
Soft Tissue Sarcoma Market to Evolve Rapidly Over the Next Decade by 2034, Delve …
The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Soft Tissue Sarcoma pipeline products will significantly revolutionize the Soft Tissue Sarcoma market dynamics.
DelveInsight's "Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Soft Tissue Sarcoma, historical and forecasted epidemiology as well as the Soft Tissue…
More Releases for Conjugates
Global Cancer Antibody Drug Conjugates Market
Global Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030 Report Finding & Inclusions:
• Global Cancer Antibody Drug Conjugates Market: 2020 - 2030
• Global Cancer Antibody Drug Conjugates Market Opportunity > US$ 50 Billion By 2030
• Approved Cancer Antibody Drug Conjugates: 16 Drugs
• Approved Cancer Antibody Drug Conjugates Sales Insights, Patent, Dosage and Price Analysis
• Cancer Antibody Drug Conjugates In Clinical Trials: > 500 Drugs
• Cancer Antibody Drug Conjugates Clinical…
Bispecific Antibody Drug Conjugates Development
The development of bispecific antibody drug conjugates (ADCs) marks a significant advancement in the field of targeted cancer therapy. These innovative molecules combine the specificity of bispecific antibodies with the powerful cytotoxic effects of drug conjugates, creating a new class of therapeutic agents that hold great promise for treating complex and resistant cancers. The process of developing these ADCs involves intricate design, engineering, and testing to ensure their safety, efficacy,…
DLL3 Antibody-Drug Conjugates: Mechanisms and Efficacy
Antibody-drug conjugates (ADCs) represent a revolutionary approach in cancer treatment, combining the targeting capabilities of antibodies with the cytotoxic power of chemotherapy. DLL3 (Delta-Like Ligand 3) has emerged as a promising target for ADCs, particularly in the treatment of small cell lung cancer (SCLC) and other neuroendocrine tumors. This article explores the mechanisms and efficacy of DLL3 ADCs, shedding light on their potential in modern oncology.
Download Report:
https://www.kuickresearch.com/report-dll3-targeted-therapies-dll3-cancer-therapies-dll3-protien-dll3-cancer-drugs-delta-like-ligand-3-dll3-gene-dll3-expression-dll3-amgen-dll3-inhibitor
DLL3 is a…
Radionuclide Drug Conjugates (RDC) Market Minimizing Side Effects, Maximizing Im …
Radionuclide Drug Conjugates (RDCs) Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radionuclide Drug Conjugates (RDCs) Market Size, Share & Trends Analysis Report By Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma, Others)- Market Outlook…
Oncology Antibody Drug Conjugates Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Oncology Antibody Drug Conjugates Market is projected to grow from USD 9.87 billion in 2022 to USD 22.48 billion at a CAGR value of 12.4% from 2022 to 2027.
Pfizer Inc., Astellas Pharma Inc., Gilead Sciences, Inc., GlaxoSmithKline, F. Hoffmann-La Roche AG, Daiichi Sankyo, AstraZeneca, Sanofi, AbbVie, Merck & Co., Byondis, RemeGen, ImmunoGen, Seagen, Rakuten Medical,…
Global Antibody Drug Conjugates Market Insights, Forecast
Antibody Drug Conjugates are highly effective biopharmaceutical medications designed as a targeted therapy for cancer treatment. The preparation process of ADC’s involves great difficulty, inspite of these hurdles recently approved ADC’s have proved their worth for treatment of cancer. Thus, there is a strong pipeline of ADC’s that promises revolutionary changes in area of targeted therapy for cancer treatment. This market is driven by elements such as continuous improvement…
